Skip to content

Interest Income at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$229M-31.0%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
$3.57M-35.2%
Regenxbio logo
RegenxbioRGNX
$2M-19.9%
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
$2.33M-17.6%
Xencor logo
XencorXNCR
$5.46M-27.6%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$1.33M-58.6%

Other financials

Income statement

See full
Operating income-$10.8M-131%
Net income-$10.1M-122%
EPS (diluted)-$0.18-20.0%

Balance sheet

See full
Cash & equivalents$79.3M+398%
Total debt$1.0M-2.0%
Total equity$84.4M+779%
Total assets$95.8M+382%

Cash flow

See full
Operating cash flow-$9.8M-483%
CapEx$32.5K-52.0%
Free cash flow-$9.9M-462%

Valuation

See full
Market cap$691.97M+1,008%
Enterprise value$613.75M+1,190%

Returns & leverage

See full
Return on equity-74.4%-18.6pp
Debt / equity-0.1×
Current ratio8.8×+7.0×

Where this comes from

Reported directly by Immix Biopharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immix Biopharma, Inc.'s interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immix Biopharma, Inc.'s interest income?
Immix Biopharma, Inc. (IMMX) reported interest income of $717.17K in Q1 2026.
How has Immix Biopharma, Inc.'s interest income changed year-over-year?
Immix Biopharma, Inc.'s interest income increased by 377.4% year-over-year, from $150.22K to $717.17K.
What is the long-term trend for Immix Biopharma, Inc.'s interest income?
Over 2 years (2023 to 2025), Immix Biopharma, Inc.'s interest income has grown at a -1.5% compound annual growth rate (CAGR), from $572.01K to $555.53K.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.